Full-Time

Senior Business Process & Systems Specialist

Posted on 5/9/2026

RELX

RELX

1,001-5,000 employees

Global information analytics and decision tools

No salary listed

London, UK + 1 more

More locations: Woking, UK

In Person

Category
Business & Strategy (2)
,
Required Skills
Salesforce
JIRA
Requirements
  • Significant experience within Sales Operations, supporting complex, multi-brand environments.
  • Strong hands-on experience with Salesforce, sales efficiency tools, and wider sales technology stacks such as third-party integrations, Robotic Process Automation automation, and low-code tools such as Power Apps.
  • Highly analytical with strong problem-solving skills, able to deconstruct complex business and system issues, assess data and user experience, and translate requirements into effective solutions.
  • Strong experience in Salesforce reporting and dashboard creation, using data to support decision-making, user insight, and continuous improvement.
  • Experience leading the delivery of complex business process and system initiatives from concept through to deployment.
  • Excellent written and verbal communication skills, able to clearly articulate best practice, process changes, and complex topics to both technical and non-technical audiences.
  • Experience supporting requirements gathering and working with stakeholders to document business needs into clear JIRA tickets, user stories, and acceptance criteria that enable effective development delivery.
  • Strong organisational and prioritisation skills, managing multiple initiatives across brands while aligning work to Data Services objectives and constructively challenging where required.
  • Expertise in creating, maintaining, and governing high-quality documentation, including standard operating procedures and implementation artefacts.
  • Ability to work effectively within large, cross-functional teams, providing leadership in workload prioritisation and supporting UAT and functional testing, including test scenario creation, execution, and issue triage.
  • Resilient, accountable, enthusiastic, and results-focused, with a proactive, self-motivated mindset and the ability to operate effectively in changing or ambiguous environments.
Responsibilities
  • Researching and analysing the brands existing business processes using data to support the identification of areas for improving efficiency and reducing deal cycle time, creating increased alignment across data services.
  • Support requirements gathering across sales and operations initiatives, working with stakeholders to help translate business needs into detailed JIRA tickets and user stories that enable efficient and high-quality delivery..
  • Develop and present business cases for process improvements, ensuring alignment with business priorities and Data Services Sales Operations objectives.
  • Act as a subject-matter expert for sales processes and systems, ensuring best-practice adoption across Data Services sales users.
  • Use data, reporting, and Salesforce dashboards to evidence issues, track performance, and support continuous improvement recommendations.
  • Own and manage the delivery of process and system changes from concept through deployment, partnering with the wider Data Services Sales Operations Team as required.
  • Develop, document, and maintain standard operating procedures to ensure consistent, scalable, and well-governed processes.
  • Lead change communications, ensuring clear cascade of process updates and system impacts to sales users and the Data Services Sales Operations Team.
  • Oversee UAT processes and functional testing, including test scenario creation, execution support, and issue triage to ensure robust releases.
  • Monitor and address data quality issues, ensuring systems support accurate reporting, reliable insights, and effective decision-making.

RELX is a global provider of information-based analytics and decision tools for professionals across scientific, technical, medical, legal, risk, business, and exhibitions industries. It operates in four segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. Its products combine large datasets, analytics, and decision-support tools to help researchers, healthcare professionals, lawyers, and business leaders make informed choices, improve productivity, and achieve better outcomes. Revenue mainly comes from subscriptions, with additional income from transactional sales and advertising. RELX differentiates itself through its deep data assets, specialized industry knowledge, and multi-segment offerings that span content, analytics, and decision-support services. The company pursues a goal of delivering trusted information and insights while supporting corporate responsibility and alignment with the UN SDGs through its products and partnerships.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1894

Simplify Jobs

Simplify's Take

What believers are saying

  • 7% revenue growth and 9% adjusted operating profit increase in 2025 from AI tool adoption.
  • LexisNexis customers increasingly adopt AI-assisted tools, driving subscription revenue expansion.
  • Government sector expansion through enhanced fraud detection capabilities protects critical social safety nets.

What critics are saying

  • Anthropic's legal AI agent directly competes with Lexis+AI, eroding subscription revenue within 6-12 months.
  • EU AI Act enforcement July 2026 classifies Protégé as high-risk, imposing fines up to 6% revenue.
  • Thomson Reuters' Westlaw Precision AI captured 15% market share through superior case prediction accuracy.

What makes RELX unique

  • Proprietary database of 200 billion legal documents dating to 1873 cannot be replicated by AI providers.
  • Acquired Doctrine in 2025 to strengthen AI capabilities across European legal market segments.
  • Appointed fraud prevention expert Glenn Prager April 2025 to enhance government risk solutions.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at RELX who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Family Planning Benefits

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Remote Work Options

Company News

Business Insider
Mar 1st, 2026
LexisNexis CEO dismisses AI threat as company reports 7% revenue growth

LexisNexis CEO Sean Fitzpatrick has dismissed investor concerns that AI threatens the legal software giant, saying proprietary data gives it a competitive advantage. Shares of parent company Relx fell 14% on 3 February following Anthropic's launch of an AI agent that drafts legal briefs, and are down 17% year-to-date. Fitzpatrick said LexisNexis's database of 200 billion legal documents, including content from Shepard's Citations dating to 1873, cannot be replicated by AI model makers. The company doesn't license its proprietary data to general-purpose AI providers. Relx reported 7% revenue growth for 2025 and 9% increase in adjusted operating profit, driven by customers adopting AI tools. LexisNexis is hiring and hasn't conducted AI-related redundancies.

Yahoo Finance
Feb 22nd, 2026
RELX's LexisNexis launches AI-powered identity management platform for healthcare

LexisNexis Risk Solutions, a wholly owned subsidiary of RELX, has launched a new identity management platform for the healthcare sector. Announced on 19 February, the tool combines identity verification, matching and enrichment capabilities with AI-powered authentication to enhance security throughout patients' healthcare journeys. The platform integrates LexisNexis IDVerse and offers enhanced identity verification, resolution and fraud protection. For healthcare professionals, it accelerates onboarding processes, automates processing and provides digital checks to prevent fraud. RELX is a global information and analytics company serving professional and business customers across scientific, technical, medical, legal and risk management markets.

PR Newswire
Jun 4th, 2025
Elsevier Unveils Rigorous Evaluation Framework To Mitigate Risk In Generative Ai Clinical Decision Support Tools

Clinician-centered framework will be featured in upcoming issue of the Open AccessJournal of the American Medical Informatics Association (JAMIA)Initial evaluations of ClinicalKey AI show high accuracy and usefulness in responses amongst cliniciansNEW YORK, June 4, 2025 /PRNewswire/ -- Elsevier, a global leader in medical information and data analytics, unveiled a groundbreaking evaluation framework for assessing the performance and safety of generative AI-powered clinical reference tools. This innovative approach has been developed for all Elsevier Health generative AI solutions, including ClinicalKey AI, Elsevier's advanced clinical decision support platform, and sets a new standard for responsible AI integration in healthcare. It will be featured in a future issue of the Open Access Journal of the American Medical Informatics Association (JAMIA).The framework, designed with input from clinical subject matter experts across multiple specialties, evaluates AI-generated responses along five critical dimensions: query comprehension, response helpfulness, correctness, completeness, and potential for clinical harm. It serves as a comprehensive assessment to ensure that AI-powered tools not only provide accurate and relevant information but also align with the practical and current needs of healthcare professionals at the point of care.Omry Bigger, President of Clinical Solutions at Elsevier: "This evaluation framework not only supports innovation and advancements to improve patient care but adds an extra layer of review and assessment to ensure physicians are armed with the most accurate information possible. It's a critical step in the implementation of responsible AI for healthcare providers and patients."In a recent evaluation study of ClinicalKey AI, Elsevier worked with a panel of 41-board certified physicians and clinical pharmacists to rigorously test responses generated by the tool for a diverse set of clinical queries. That panel evaluated 426 query-response pairs, and results demonstrated impressive performance, with 94.4% of responses rated as helpful, 95.5% assessed as completely correct, with just 0.47% flagged for potential improvements.Leah Livingston, Director of Generative AI Evaluation for Health Markets at Elsevier, said: "These results reflect not just strong performance, but the real value of bringing clinicians into the evaluation process

PharmiWeb.com
May 7th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World’S Most Comprehensive Biomedical Database

London, 6 May 2025 – Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device. Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and RD organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence

PR Newswire
May 6th, 2025
Elsevier Adds Half A Million Records From Clinicaltrials.Gov To Embase, Enabling A Seamless Search Experience In The World'S Most Comprehensive Biomedical Database

Data from studies conducted in more than 200 countries supports greater access to research and facilitates systematic reviews, clinical trial design, medical device approvals and improved drug safetyLONDON, May 6, 2025 /PRNewswire/ -- Elsevier, a global leader in information and analytics, is announcing the addition of half a million records from ClinicalTrials.gov to its leading biomedical literature database, Embase. The integration will enable researchers to seamlessly view high-quality information on clinical research studies and their results alongside the peer-reviewed literature, in-press publications and conference abstracts already available in Embase. Researchers will be able to conduct more comprehensive evidence and literature searches while having the confidence they will never miss important updates relevant to their drug, therapy, or medical device.Clinical trials data is a vital component of biomedical literature search, helping pharmaceutical and medical device companies stay informed about the latest scientific advancements, regulatory requirements, and competitive insights to support evidence-based decision-making. However, gathering data from multiple sources is currently prone to errors and is time-consuming, such as the duplication of search results, which slows research and regulatory processes. As new therapies and devices are developed and R&D organizations seek collaborative partners, they must undertake thorough searches and justifications of evidence. This process becomes challenging when data must be sourced from differing platforms, and regulatory and compliance requirements continue to evolve.The addition of ClinicalTrials.gov data to Embase will improve researcher workflows by making clinical data searchable within Embase's user-friendly interface